A Phase 2 Study of Increased-Dose Abiraterone Acetate in Patients with Castration Resistant Prostate Cancer (CRPC)
To find out how effective, an increased dose of the study drug (Abiraterone Acetate) and prednisone are against prostate cancer, based on time to prostate-specific antigen (PSA) progression, and/or progression by imaging (CT scan, bone scan) and, to find out the side effects of the study drug.
Metastatic Castrate Resistant Prostate Cancer
* Subjects must have prostate cancer which has spread outside the prostate and is progressing by PSA.
* Subjects have not had any chemotherapy.
* Subjects should not have history of pituitary or adrenal dysfunction.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
UCSF Helen Diller Family Comprehensive Cancer Center